To formalize its advisory and advocacy roles within the organization, the AACR established a governance structure for the AACR Academy in 2018. This leadership body consists of an elected president-elect, who will serve for one year and then transition to a two-year term as Academy president at the AACR Annual Meeting 2019, and six elected Steering Committee members who will serve three-year terms.
The following AACR Fellows are inaugural members of the AACR Academy leadership body:
At a ceremony on the evening before the Annual Meeting in Chicago, Illinois, the 2018 class of Fellows of the AACR Academy was formally inducted.
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California
For characterizing the significance of cancer susceptibility genes, notably BRCA2, in the pathogenesis of cancer, and for his contributions to the establishment of PARP inhibitors as effective therapeutic options for the treatment of various cancers.
Netherlands Cancer Institute
Amsterdam, Netherlands
For establishing innovative strategies to categorize biomarkers of treatment response and effective treatment combinations, and for pioneering the use of genetic screening tests to identify and stratify individuals at risk of developing breast cancer.
University of Texas Southwestern Medical Center
Dallas, Texas
For his discovery of Toll-like receptors and for deciphering the biological mechanisms and signaling events that govern tumor necrosis factor-mediated inflammation and innate immune system activation.
City of Hope National Medical Center
Duarte, California
For elucidating the fundamental mechanisms of natural killer cell development and immune surveillance, and for his commitment to advancing cancer health disparities research and promoting the collection and use of clinical samples to guide screening, treatment, and surveillance protocols.
Ludwig Institute for Cancer Research
New York, New York
The Wistar Institute
Philadelphia, Pennsylvania
For illuminating mechanistic links between the MYC oncogene and cellular metabolism, and for defining how tumor cell utilization of various energy sources contributes to cancer progression.
Fred Hutchinson Cancer Research Center
Seattle, Washington
For identifying genetic drivers of various hematologic malignancies including leukemia, myelodysplastic syndrome, and myeloproliferative disease, and for his contributions to the development of monoclonal antibody-based immunotherapeutics.
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
For her central discoveries in the fields of transcriptional regulation, lymphocyte differentiation, inflammation, and osteobiology, and for her trailblazing efforts to improve access to care, health policy, and medical education.
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
For her groundbreaking efforts dedicated to the development of cancer vaccines and vaccine combinations that bypass tumor-associated immunotolerance, and for exploiting genomic and proteomic technologies to define biomarkers required for cancer onset, progression, and metastasis.
Juno Therapeutics
Los Altos Hills, California
For defining molecular mechanisms of intracellular trafficking, translation, and protein assembly, and for leading the creation of national and international programs to support the spectrum of cancer research, resulting in improved cancer diagnosis and treatment strategies.
Stanford University School of Medicine
Stanford, California
For his pioneering discovery of the structure and function of nucleosomes, and for revolutionizing the understanding of the molecular machinery and orchestrated mechanisms required for eukaryotic gene transcription.
Calico Life Sciences LLC
South San Francisco, California
For his visionary leadership and relentless commitment to the discovery and development of targeted therapeutics for the treatment of various malignancies, including HER2/neu monoclonal antibodies for the treatment of breast cancer.
National Cancer Institute,
Bethesda, Maryland
For his seminal contributions to stem cell biology and to demonstrating the relationship between tumor suppressor activation, cell cycle control, cellular senescence, and molecular aging in tumorigenesis.
The ability of the AACR Scientific Achievement Awards program to identify paradigm-shifting excellence in cancer research was confirmed in October 2018 when AACR member and former member of the AACR Board of Directors James P. Allison, PhD, FAACR, was awarded the Nobel Prize in Physiology or Medicine for his shared discovery with colleague Tasuku Honjo, MD, PhD, of cancer therapy by inhibition of negative immune regulation. Before culminating in this recognition by the international scientific community, Dr. Allison’s career was marked by several AACR awards, including:
By honoring exceptional scientists in all scientific areas and at all career stages, AACR Scientific Achievement Awards highlight the critical steps along the path of progress against cancer.
City of Hope Comprehensive Cancer Center
Duarte, California
Institute of Cancer Research and Royal Marsden
Sutton, United Kingdom
University of Illinois at Urbana-Champaign
Urbana, Illinois
Memorial Sloan Kettering Cancer Center
New York, New York
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy Center at University of California Los Angeles
Los Angeles, California
University of Texas MD Anderson Cancer Center
Houston, Texas
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
Rutgers Cancer Institute of New Jersey
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
University of Southern California Keck School of Medicine
Los Angeles, California
The Salk Institute
La Jolla, California
Knight Cancer Institute
Portland, Oregon
Genomic Approaches to Preventing and Treating Asian-Prevalent Cancers Team
Team Leader
Duke-NUS Medical School
Cancer Science Institute of Singapore
Singapore
Duke-NUS Medical School
Cancer Science Institute of Singapore
Singapore
Duke-NUS Medical School
Singapore
National Cancer Centre Singapore
Duke-NUS Medical School
Singapore
National Cancer Centre Singapore
Agency for Science, Technology and Research (A*STAR)
Singapore
Agency for Science, Technology and Research (A*STAR)
Singapore
The University of Tokyo
National Cancer Center
Tokyo, Japan
Khon Kaen University
Khon Kaen, Thailand
Khon Kaen University
Khon Kaen, Thailand
Chang Gung Memorial Hospital
Linkou, Taiwan
Chang Gung Memorial Hospital
Linkou, Taiwan
University of California Berkeley
Berkeley, California
New York University Langone Medical Center
New York, New York
Dana-Farber Cancer Institute
Boston, Massachusetts
Medical University of South Carolina
Charleston, South Carolina
University of Califonia San Francisco
San Francisco, California